Caricamento...

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma

Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in bortezomib-naïve pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Fostier, Karel, De Becker, Ann, Schots, Rik
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2012
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3463411/
https://ncbi.nlm.nih.gov/pubmed/23055749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S28911
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !